NEXI

0.00010.00%
DP

Daniel P. Bednarik

Senior Vice President of Molecular Engineering & Protein Design

Dr. Daniel P. Bednarik, Ph.D. has been Senior Vice President of Molecular Engineering & Protein Design at NexImmune, Inc. since May 11, 2017. Dr. Bednarik has experience as a translational scientist and executive specializing in moving promising technologies into product development. He has been Director of Research Advisory Board at Ablitech, Inc., since 2012. He serves as Director of Genomics and Bioinformatics for Cardiome Pharma Corporation. He served as Vice President, Molecular Engineering Unit at Intrexon Corp. where he led a team of scientists developing innovative methods for cellular therapies for cancer. He served as Vice President of Cardiovascular Biology of Artesian Therapeutics, Inc. and was its Co-Founder. Dr. Bednárik held senior positions at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. and led various projects focused on translational medicine spanning several therapeutic areas including cancer and cardiovascular diseases. He is a seasoned scientific manager with experience in the disciplines of cardiovascular disease and translational research. Prior to joining Artesian Therapeutics, he served as the Director of Scientific Product Development, Cardiovascular Program, Gene Logic Inc., where he successfully designed and launched the first and the largest Affymetrix GeneChip™ database representative of cardiovascular disease in collaboration with key academic and pharmaceutical subscribers. This data collection (CV DataSuite®) has employed human and animal model disease biosamples as pivotal and functionally validated representatives of disease progression. He served to assist Gene Logic’s senior management to successfully bridge critical gaps between science and business. From 1993 to 1997, he served as a senior scientist with Human Genome Sciences Inc. (HGS), where he discovered and co-patented over 200 novel human genes, many of which are now proprietary to HGS and Glaxo-SmithKline (GSK). In 1989, he served as Chief of Molecular Genetics, The Centers for Disease Control and Prevention where he mapped novel mechanisms for HIV-1 latency and also as Assistant Professor of Pathology, the Winship Cancer Center, Emory University School of Medicine, where he investigated the role of viral infection as an etiological mechanism for idiopathic cardiomyopathy. Prior to that, he was a postdoctoral fellow and subsequently a junior faculty member at the Johns Hopkins Oncology Center. He completed a post-doctoral fellowship at The Johns Hopkins University Oncology Center. Dr. Bednarik holds B.A. in biology from Rider University and Ph.D. in biochemistry from Temple University School of Medicine.

Positions